Additionally, the 36-month beta value for ANVS is 1.62. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for ANVS is 16.62M and currently, short sellers hold a 12.72% ratio of that float. The average trading volume of ANVS on June 25, 2025 was 448.12K shares.
ANVS) stock’s latest price update
The stock price of Annovis Bio Inc (NYSE: ANVS) has jumped by 732070 compared to previous close of 2.64. Despite this, the company has seen a gain of 8.13% in its stock price over the last five trading days. globenewswire.com reported 2025-06-19 that MALVERN, Pa., June 19, 2025 (GLOBE NEWSWIRE) — Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced it received notification (the “Acceptance Letter”) from the New York Stock Exchange (“NYSE”) that the NYSE has accepted the Company’s previously-submitted plan (the “Plan”) to regain compliance with the NYSE’s continued listing standards relating to minimum market capitalization and stockholders’ equity.
ANVS’s Market Performance
ANVS’s stock has risen by 8.13% in the past week, with a monthly rise of 47.12% and a quarterly rise of 65.41%. The volatility ratio for the week is 7.83% while the volatility levels for the last 30 days are 8.27% for Annovis Bio Inc The simple moving average for the past 20 days is 11.43% for ANVS’s stock, with a -32.63% simple moving average for the past 200 days.
Analysts’ Opinion of ANVS
Maxim Group, on the other hand, stated in their research note that they expect to see ANVS reach a price target of $25. The rating they have provided for ANVS stocks is “Buy” according to the report published on October 25th, 2024.
Canaccord Genuity gave a rating of “Buy” to ANVS, setting the target price at $36 in the report published on December 29th of the previous year.
ANVS Trading at 48.77% from the 50-Day Moving Average
After a stumble in the market that brought ANVS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -82.89% of loss for the given period.
Stock Fundamentals for ANVS
The total capital return value is set at -0.78. Equity return is now at value -280.78, with -168.22 for asset returns.
Currently, EBITDA for the company is -22.74 million with net debt to EBITDA at 1.18. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.68.
Conclusion
In conclusion, Annovis Bio Inc (ANVS) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
